Skip to main content
Clinical Trials/NCT02638324
NCT02638324
Terminated
N/A

Supportive Treatment of Severe Heart Failure by Renal Denervation

Turku University Hospital1 site in 1 country40 target enrollmentDecember 1, 2014
ConditionsHeart Failure

Overview

Phase
N/A
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Turku University Hospital
Enrollment
40
Locations
1
Primary Endpoint
6-minute walking test
Status
Terminated
Last Updated
5 years ago

Overview

Brief Summary

The overactivity of sympathetic nervous system is worsening the hemodynamic state of heart failure patients. The present study is planned to reduce the sympathetic tone in patients with severe heart failure by renal nervous denervation.

Detailed Description

The patient population consists of heart failure patients who are not responding properly to medication and biventricular pacing therapy. The inappropriate response to these therapies is evaluated by patient history (NYHA III-IV), echocardiography (EF \< 45%), 6-minute walking test (\<440m) and measurements of P-ProBNP. The patients who fulfill the inclusion criteria will undergo renal nervous denervation. The patients will be followed up with the same methods as they were recruited to the study (by patient history (NYHA III-IV), echocardiography (EF \< 45%), 6-minute walking test (\<440m) and measurements of P-ProBNP). The overall time of follow-up will be 24 months. The patients are randomised according to the waiting list principle in a manner to 1:1. The waiting time will be 6 months.

Registry
clinicaltrials.gov
Start Date
December 1, 2014
End Date
January 30, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • NYHA III-IV
  • ejection fraction \<45 %
  • 6-minute walking test under 440m

Exclusion Criteria

  • Unstable hemodynamic state
  • uncooperation

Outcomes

Primary Outcomes

6-minute walking test

Time Frame: 24 months

Composite outcome measure

Secondary Outcomes

  • Cardiac echocardiography(24 months)
  • Patient history(24 months)
  • P-proBNP(24 months)

Study Sites (1)

Loading locations...

Similar Trials